US biotech Abcuro has reeled in $200 million in third-round financing that should allow it to complete its pivotal trial of ...

The funding will be used to complete the Phase II/III trial of ulviprubart, and to support commercial launch preparation.

Abcuro Inc. has raised a $200 million Series C financing to fund late-stage development and support commercial launch ...

Funding was led by New Enterprise Associates, with participation from Foresite Capital and multiple other investors.

Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells, today announced the ...

Sanofi-backed Abcuro has secured $200 million in series C funds to power its anti-KLRG1 antibody through a phase 2/3 muscle ...

Massachusetts, USA-based cell therapy specialist Abcuro today announced the closing of a $200 million Series C financing.

At JP Morgan last month, pharmaphorum editor-in-chief Jonah Comstock caught up with Paul Hastings, the CEO of Nkarta, to talk ...

Exposures to silica dust, solvents or heavy metals increase the likelihood of developing various forms of myositis, ...

In this article, we are going to take a look at where International Business Machines Corporation (NYSE:IBM) stands against other AI stocks trending on news and analyst ratings. In a surprising ...

Infrastructure is optimized for infusing AI into mission-critical transactions and tightly integrated with IBM Software including Red Hat for accelerated hybrid cloud benefits. The Financing ...